Background The monitoring of BCR-ABL transcript levels by real-time quantitative
polymerase chain reaction (RT-qPCR) has become important to assess minimal residual …

Molecular monitoring of BCR–ABL transcript levels by real-time quantitative PCR is
increasingly used to assess treatment response in patients with chronic myeloid leukaemia …

BACKGROUND AND OBJECTIVES: The most common translocation in chronic myeloid
leukemia (CML) t (9; 22)(q34; q22) produces the BCR/ABL fusion gene. We set up and …

OBJECTIVE: Of 140 chronic myeloid leukemia patients responding to imatinib with complete
cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at≥ 0.1% level in a …

Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the
peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to …

The optimal management of malignant haematological disorders depend on the degree of
tumor load reduction after therapy. Chronic myeloid leukemia constitutes a clinical model for …

Accurate quantification of minimal residual disease (MRD) during treatment of chronic
myeloid leukemia (CML) guides clinical decisions. The conventional MRD method, RQ-PCR …

Bone marrow BCR‐ABL transcript levels were monitored serially by real‐time quantitative
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …

Imatinib mesylate, binding to the inactive conformation of Bcr‐Abl tyrosine kinase and
suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic …

Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the
Philadelphia chromosome, have drastically improved the outcomes for patients with chronic …